Keryx Fights Investor's Bid To Lead Kidney Drug Stock Suit

Law360, Boston (June 19, 2019, 9:48 PM EDT) -- A Keryx investor seeking to lead a shareholder class action over a 2016 stock drop shouldn’t head up the suit because his shares were bought through a now-defunct trust and the vital information allegedly hid by the company was actually disclosed, a Massachusetts federal judge heard Wednesday.

In a hearing over class certification and Keryx Biopharmaceuticals Inc.'s motion for a judgment to escape the suit, attorneys for the Boston-based pharmaceutical company claimed a number of factors should defeat shareholder Tim Karth’s efforts to certify and lead a class. One such issue is that he bought his shares through a trust that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Subscribers Only

Date Filed

August 26, 2016

Law Firms

Companies

Government Agencies

Judge Analytics